Stryker Corporation

SYK

Healthcare Medical Devices

Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024.

Revenue
+7.64%
EPS
−11.8%
Free cash flow
−19.4%
Total debt
−10.0%

Quarter to September 2026, against a year earlier

309.64 2.75 −0.88%
Market cap
$118.9B
P/E
32.7×
Fwd P/E FY26e
26.7×
Dividend yield
1.14%
F-score
5/9
ROIC
9.67%
Net debt / EBITDA
1.9×
Payout ratio
0.4×

Stryker Corporation (SYK) news

The news and the share price important stories, numbered as below

Share price since 16 October +5.1%

Stories the last two months, newest first

  1. 2 Guidance ·

    Stryker lowers 2026 organic sales growth outlook to 6.5%–7%

    Stryker lowered its 2026 organic sales growth outlook, with orthopaedic softness among the cited factors. Management pointed to weaker hip and knee trends, supply constraints and execution risks, and expected fourth-quarter growth similar to the third quarter’s 7.7%. The articles also noted stronger performance in MedSurg and Neurotechnology and that the SAP rollout is complete.

    Reported by 2: Trefis · Trefis

  2. Commentary ·

    Stryker valuation models give mixed views of its shares

    A discounted cash flow model based on $4.6 billion in trailing free cash flow and projected growth suggested Stryker shares may be undervalued. Community valuations were mixed: one scenario saw the stock as roughly fairly valued, while another estimated it was 8% overvalued. The analysis also flagged manufacturing disruptions, an investigation in the Peripheral Vascular unit and insider selling.

    Reported by Simply Wall St.

  3. Commentary ·

    Stryker put options show unusually high implied volatility

    Stryker’s Dec. 18, 2026 $560 put had unusually high implied volatility, signaling options traders expect a potentially large move. Over the past 30 days, six analysts cut current-quarter earnings estimates and none raised them, lowering consensus from $5.10 to $5.03 per share. Stryker carries a Zacks Rank #4 (Sell).

    Reported by Zacks

  4. 1 Results ·

    Stryker reports $6.52 billion in third-quarter revenue

    Stryker’s Q3 2026 revenue of $6.52 billion and adjusted EPS of $3.52 missed analyst estimates. Operating margin fell to 15.9% from 18.7%, as softness in U.S. hip and knee procedures and execution disruptions weighed on Orthopaedics. MedSurg and Neurotechnology remained strong, while management lowered full-year adjusted EPS guidance and expected continued elective-procedure weakness and peripheral vascular supply constraints.

    Reported by 2: Simply Wall St. · StockStory

More headlines